Browsing Clinical Studies by author "Judson, Ian"
Now showing items 1-20 of 41
-
Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
Grünwald, V; Litière, S; Young, R; Messiou, C; Lia, M; Wardelmann, E; van der Graaf, W; Gronchi, A; Judson, I; EORTC STBSG (2016-09)Anthracycline-based chemotherapy remains the mainstay of first-line treatment in metastatic or advanced soft-tissue sarcoma (STS). Age, performance status, tumour histology and tumour grade are recognised prognostic factors; ... -
The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma.
Lee, ATJ; Chew, W; Wilding, CP; Guljar, N; Smith, MJ; Strauss, DC; Fisher, C; Hayes, AJ; Judson, I; Thway, K; Jones, RL; Huang, PH (2019-10-10)The characterisation and clinical relevance of tumour-infiltrating lymphocytes (TILs) in leiomyosarcoma (LMS), a subtype of soft tissue sarcoma that exhibits histological heterogeneity, is not established. The use of tissue ... -
Advances in the treatment of gastrointestinal stromal tumours.
Judson, I; Demetri, G (2007-09)Imatinib, a selective tyrosine kinase inhibitor, is currently the standard of care first-line treatment for unresectable or metastatic gastrointestinal stromal tumour (GIST), improving survival time and delaying disease ... -
Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response.
Libertini, M; Mitra, I; van der Graaf, WTA; Miah, AB; Judson, I; Jones, RL; Thomas, K; Moskovic, E; Szucs, Z; Benson, C; Messiou, C (2018-01)Background:One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, ... -
Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.
Olmos, D; Tan, DSW; Jones, RL; Judson, IR (2010-05)Two decades have elapsed since insulin-like growth factor-1 receptor (IGF-1R) signaling was initially implicated in sarcoma biology to the first clinical experience of IGF-1R blockade in sarcoma. During these 21 years, the ... -
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
Judson, I; Morden, JP; Kilburn, L; Leahy, M; Benson, C; Bhadri, V; Campbell-Hewson, Q; Cubedo, R; Dangoor, A; Fox, L; Hennig, I; Jarman, K; Joubert, W; Kernaghan, S; López Pousa, A; McNeil, C; Seddon, B; Snowdon, C; Tattersall, M; Toms, C; Martinez Trufero, J; Bliss, JM (2019-07)<h4>Background</h4>Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised ... -
Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study.
Zhang, AY; Judson, I; Benson, C; Wunder, JS; Ray-Coquard, I; Grimer, RJ; Quek, R; Wong, E; Miah, AB; Ferguson, PC; Dufresne, A; Teh, JYH; Stockler, M; Tattersall, MHN (2017-07)An increasing number and proportion of cancer patients with apparently localised disease are treated with chemotherapy and radiation therapy in contemporary oncology practice. In a pilot study of radiation-induced sarcoma ... -
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Demetri, GD; Antonescu, CR; Bjerkehagen, B; Bovée, JVMG; Boye, K; Chacón, M; Dei Tos, AP; Desai, J; Fletcher, JA; Gelderblom, H; George, S; Gronchi, A; Haas, RL; Hindi, N; Hohenberger, P; Joensuu, H; Jones, RL; Judson, I; Kang, Y-K; Kawai, A; Lazar, AJ; Le Cesne, A; Maestro, R; Maki, RG; Martín, J; Patel, S; Penault-Llorca, F; Premanand Raut, C; Rutkowski, P; Safwat, A; Sbaraglia, M; Schaefer, I-M; Shen, L; Serrano, C; Schöffski, P; Stacchiotti, S; Sundby Hall, K; Tap, WD; Thomas, DM; Trent, J; Valverde, C; van der Graaf, WTA; von Mehren, M; Wagner, A; Wardelmann, E; Naito, Y; Zalcberg, J; Blay, J-Y (2020-11)Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new ... -
Dichloroacetate induces autophagy in colorectal cancer cells and tumours.
Lin, G; Hill, DK; Andrejeva, G; Boult, JKR; Troy, H; Fong, A-CLFWT; Orton, MR; Panek, R; Parkes, HG; Jafar, M; Koh, D-M; Robinson, SP; Judson, IR; Griffiths, JR; Leach, MO; Eykyn, TR; Chung, Y-L (2014-07)<h4>Background</h4>Dichloroacetate (DCA) has been found to have antitumour properties.<h4>Methods</h4>We investigated the cellular and metabolic responses to DCA treatment and recovery in human colorectal (HT29, HCT116 WT ... -
Does palliative chemotherapy really palliate and are we measuring it correctly? A mixed methods longitudinal study of health related quality of life in advanced soft tissue sarcoma.
Gough, N; Koffman, J; Ross, JR; Riley, J; Judson, I (2019-01)OBJECTIVE:Soft tissue sarcoma (STS) is a rare cancer type that when locally advanced or metastatic, is predominantly treated with palliative chemotherapy with the aim of improving both quantity and quality of life. Given ... -
Gene expression profiling identifies distinct molecular subgroups of leiomyosarcoma with clinical relevance.
Lee, Y-F; Roe, T; Mangham, DC; Fisher, C; Grimer, RJ; Judson, I (2016-10)<h4>Background</h4>Soft tissue sarcomas are heterogeneous and a major complication in their management is that the existing classification scheme is not definitive and is still evolving. Leiomyosarcomas, a major histologic ... -
High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
Dirksen, U; Brennan, B; Le Deley, M-C; Cozic, N; van den Berg, H; Bhadri, V; Brichard, B; Claude, L; Craft, A; Amler, S; Gaspar, N; Gelderblom, H; Goldsby, R; Gorlick, R; Grier, HE; Guinbretiere, J-M; Hauser, P; Hjorth, L; Janeway, K; Juergens, H; Judson, I; Krailo, M; Kruseova, J; Kuehne, T; Ladenstein, R; Lervat, C; Lessnick, SL; Lewis, I; Linassier, C; Marec-Berard, P; Marina, N; Morland, B; Pacquement, H; Paulussen, M; Randall, RL; Ranft, A; Le Teuff, G; Wheatley, K; Whelan, J; Womer, R; Oberlin, O; Hawkins, DS; Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators (2019-12)PURPOSE:The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end ... -
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.
Ray-Coquard, I; Rizzo, E; Blay, JY; Casali, P; Judson, I; Hansen, AK; Lindner, LH; Dei Tos, AP; Gelderblom, H; Marreaud, S; Litière, S; Rutkowski, P; Hohenberger, P; Gronchi, A; van der Graaf, WT (2016-07)UtS are a group of uncommon tumors representing 1% of malignant neoplasms of the female genital tract, and 7% of sarcomas. The objective of this study was to evaluate the factors associated with the clinical behavior ... -
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)
Fresneau, B; Hackshaw, A; Hawkins, DS; Paulussen, M; Anderson, JR; Judson, I; Litiere, S; Dirksen, U; Lewis, I; van den Berg, H; Gaspar, N; Gelderblom, H; Whelan, J; Boddy, AV; Wheatley, K; Pignon, JP; De Vathaire, F; Le Deley, MC; Le Teuff, G (2017-08) -
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).
Fresneau, B; Hackshaw, A; Hawkins, DS; Paulussen, M; Anderson, JR; Judson, I; Litière, S; Dirksen, U; Lewis, I; van den Berg, H; Gaspar, N; Gelderblom, H; Whelan, J; Boddy, AV; Wheatley, K; Pignon, JP; De Vathaire, F; Le Deley, MC; Le Teuff, G (2017-08)A marginal interaction between sex and the type of alkylating agent was observed for event-free survival in the Euro-EWING99-R1 randomized controlled trial (RCT) comparing cyclophosphamide and ifosfamide in Ewing sarcoma. ... -
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
Wilding, CP; Elms, ML; Judson, I; Tan, A-C; Jones, RL; Huang, PH (2019-11-13)Introduction: Tyrosine kinases are key mediators of intracellular signaling cascades and aberrations in these proteins have been implicated in driving oncogenesis through the dysregulation of fundamental cellular processes ... -
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients.
Desmoid Tumor Working Group (2020-03)Desmoid tumor (DT; other synonymously used terms: Desmoid-type fibromatosis, aggressive fibromatosis) is a rare and locally aggressive monoclonal, fibroblastic proliferation characterised by a variable and often unpredictable ... -
Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center Experience.
Younger, E; Husson, O; Asare, B; Benson, C; Judson, I; Miah, A; Zaidi, S; Dunlop, A; Al-Muderis, O; van Houdt, WJ; Jones, RL; van der Graaf, WTA (2020-05-05)Purpose: Soft tissue sarcomas (STS) account for 8% of all cancers in adolescents and young adults (AYAs). Metastatic STS contribute significantly to disease-related mortality in this age group; however, data are limited ... -
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
Benson, C; Ray-Coquard, I; Sleijfer, S; Litière, S; Blay, J-Y; Le Cesne, A; Papai, Z; Judson, I; Schöffski, P; Chawla, S; Gil, T; Piperno-Neumann, S; Marréaud, S; Dewji, MR; van der Graaf, WTA (2016-07)Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They have a high recurrence rate following surgery, modest outcome to systemic therapy, and poor overall survival. Pazopanib is a ... -
p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib?
Noujaim, J; Gonzalez, D; Thway, K; Jones, RL; Judson, I (2016-05)Exon 11 KIT mutations are found in a majority of gastrointestinal stromal tumors (GIST) and are usually predictive of response to imatinib, a KIT, PDGFRA and ABL inhibitor. Exon 11 mutations with poor sensitivity to imatinib ...